1019021-78-3 Usage
General Description
6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxylic acid is a chemical compound with the molecular formula C9H5F3N2O2. It is a derivative of imidazo[1,2-a]pyridine-3-carboxylic acid, and the presence of a trifluoromethyl group makes it a fluorinated compound. This chemical has potential applications in pharmaceutical research and drug development, particularly in the field of medicinal chemistry. It may be used as a building block for the synthesis of new drug candidates or as a reference standard for analytical testing. The trifluoromethyl group can also impart unique properties to the compound, making it valuable for studying structure-activity relationships or as a tool for probing biological systems. Overall, 6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxylic acid has potential utility in various scientific and industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1019021-78-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,1,9,0,2 and 1 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1019021-78:
(9*1)+(8*0)+(7*1)+(6*9)+(5*0)+(4*2)+(3*1)+(2*7)+(1*8)=103
103 % 10 = 3
So 1019021-78-3 is a valid CAS Registry Number.
1019021-78-3Relevant articles and documents
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
-
Paragraph 0434, (2013/03/26)
The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
-
Page/Page column 86, (2013/03/28)
The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
